| http://www.w3.org/ns/prov#value | - BEVERLY, MA--(Marketwire - January 24, 2013) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has received results from in vivo studies conducted at Beth Israel Deaconess Medical C
|
